Occupational health examination results of dust exposed workers in Binhai New Area of Tianjin in 2019 / 公共卫生与预防医学

Objective To investigate the occupational health status of dust exposed workers in Binhai New Area of Tianjin, and to provide a scientific basis for the formulation of occupational disease prevention strategies. Methods On-duty physical examination data of dust exposed workers in Binhai New Area in 2019 were collected, and data processing and statistical analysis were conducted by Excel 2016 and SPSS22.0. Results A total of 20 898 dust exposed workers were included in the physical examination in 2019. Among them, 158 were abandoned in the examination of posterior-anterior high kV chest X-ray or digital radiography (DR) chest X-ray, 14 were abandoned in the examination of lung function, and a total of 20 726 were included in the final examination. Thirty-seven cases (0.18%) were found to be suspected of pneumoconiosis, 51 cases (0.25%) were found to be contraband, and 15 cases (0.072%) were found to be pneumoconiosis. The detection rate of abnormal chest radiograph was 4.73%, and the detection rate of abnormal lung function was 6.99%. Conclusion The detection rates of abnormal chest X-ray and pulmonary function of dust exposed workers in this area are rising with the increase of exposure time. Attention should be paid to the prevention of occupational pneumoconiosis by promoting the publicity and education of dust workers in large enterprises, strengthening the management of occupational health in collective enterprises, especially for older workers with long working years.

Progress on pharmacokinetic studies of therapeutic monoclonal antibodies / 中国药理学通报

Monoclonal antibody ( mAb ) represents a class of therapeutics experienced dramatic development over the past 30 years. Because of the tremendous differences in physicochemical and biological properties between mAbs and small molecules, the mAb therapeutics significantly differ from the chemical drugs in pharmacokinetic characteristics and underlying mechanisms. Full understanding of those characteristics and mechanisms may efficiently guide the screening and development of mAb medi-cines, and would well support their safety evaluation and clinical dosage regimen designing. This review is to summarize pharma-cokinetics and underlying mechanisms of mAbs from the aspects of absorption, distribution and elimination, as well as the ap-proaches for prediction of mAb pharmacokinetics in humans.